The Milwaukee Journal Sentinel has a puff piece on GE Healthcare. This story describes how GE is leveraging its acquisition of Amersham with its existing medical device business to target “personalized” medicine.  Personalized medicine is the selection (and eventually the formulation) of drug therapies based on the patients DNA.